A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications in Subjects With Early Decompensated Liver Cirrhosis
Latest Information Update: 13 Jan 2022
At a glance
- Drugs Rifaximin (Primary) ; Rifaximin (Primary)
- Indications Liver cirrhosis
- Focus Therapeutic Use
- Sponsors Salix Pharmaceuticals
- 15 Nov 2021 Results (n=172) assessing a demographic and baseline characteristics subgroup analysis, presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases
- 13 Oct 2020 Results of post hoc subanalysis evaluating faecal bile acid profiles in patients with early decompensated cirrhosis presented at the 28th United European Gastroenterology Week
- 19 May 2020 Results (n=98) of a post-hoc subgroup analysis assessing fecal bile acid profiles in patients with early decompensated cirrhosis treated with rifaximin soluble solid dispersion published in Gasteroenterology in conjunction with Digestive Disease Week 2020